Tarsus Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
TARS$73.83+4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consol idated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenues: | ||||
| Product sales, net | $194,569 | $118,697 | $513,868 | $299,692 |
| License fees and collaboration revenue | — | — | 16,667 | — |
| Total revenues | 194,569 | 118,697 | 530,535 | 299,692 |
| Operating expenses: | ||||
| Cost of sales | 13,894 | 8,309 | 35,403 | 19,757 |
| Research and development | 44,192 | 16,284 | 97,553 | 46,287 |
| Acquired in-process research and development | 632,176 | — | 632,176 | — |
| Selling, general and administrative | 168,021 | 108,633 | 455,147 | 296,641 |
| Change in fair value of contingent consideration | (1,620) | — | (1,620) | — |
| Total operating expenses | 856,663 | 133,226 | 1,218,659 | 362,685 |
| Loss from operations before other income (expense) | (662,094) | (14,529) | (688,124) | (62,993) |
| Other income (expense): | ||||
| Interest income | 3,777 | 4,114 | 11,197 | 11,797 |
| Interest expense | (2,185) | (2,268) | (6,469) | (6,721) |
| Gain on exchange of long-term investments | — | — | 2,812 | — |
| Loss on initial consolidation of variable interest entity | (3,281) | — | (3,281) | — |
| Other income (expense), net | 91 | 98 | (277) | (128) |
| Total other income (expense), net | (1,598) | 1,944 | 3,982 | 4,948 |
| Provision for income taxes | (4,642) | — | (9,710) | — |
| Net loss | $(668,334) | $(12,585) | $(693,852) | $(58,045) |
| Unrealized gain (loss) on marketable securities and cash equivalents | (357) | 250 | (1,295) | 110 |
| Comprehensive loss | $(668,691) | $(12,335) | $(695,147) | $(57,935) |
| Net loss per share, basic and diluted | $(14.40) | $(0.30) | $(15.67) | $(1.40) |
| Weighted-average shares outstanding, basic and diluted | 46,421,382 | 42,607,717 | 44,270,023 | 41,457,027 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.